Amy Jo Chien, Amelia S Gliwa, Siti Rahmaputri, Heidi F Dittrich, Melanie Catherine Majure, Hope S. Rugo, Michelle E. Melisko, Pamela N. Munster, John W. Park, Mark M. Moasser, Mehrdad Matloubian, Tasha Lea, Julia Rohrberg, Gregor Krings, Andrei Goga. A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):1076-1076.